Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors

Core Viewpoint - Zai Lab Limited has received approval from China's National Medical Products Administration for AUGTYRO™ (repotrectinib) to treat adult patients with solid tumors that have an NTRK gene fusion [1] Group 1: Regulatory Approval - The supplemental New Drug Application (sNDA) for AUGTYRO™ has been approved specifically for patients with locally advanced or metastatic disease, or where surgical resection is not feasible [1]